GMAB – Genmab A/S

Genmab A/S

GMAB

$29.89

Name : Genmab A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $18,398,676,992.00

EPSttm : 1.93

Genmab A/S

$29.89

0.07%

$0.02

Float Short %

0.9

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

-0.14

EPS Last/This Y

-0.02

EPS This/Next Y

-0.34

Price

29.88

Target Price

33.84

Analyst Recom

1.77

Performance Q

29.45

Relative Volume

2.15

Beta

0.97

Ticker: GMAB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-29	GMAB	29.33	0.33	0.01	1838
2025-09-30	GMAB	30.66	0.32	0.00	1853
2025-10-01	GMAB	31.77	0.31	0.30	1901
2025-10-02	GMAB	32.12	0.32	0.63	2089
2025-10-03	GMAB	33.56	0.34	0.04	2140
2025-10-06	GMAB	33.3	0.30	0.01	2373
2025-10-07	GMAB	32.63	0.29	0.51	2489
2025-10-08	GMAB	32.74	0.27	0.53	2487
2025-10-09	GMAB	31.83	0.27	0.06	2514
2025-10-10	GMAB	31.82	0.27	0.14	2514
2025-10-13	GMAB	32.67	0.27	0.01	2532
2025-10-14	GMAB	32.76	0.27	0.00	2578
2025-10-15	GMAB	32.74	0.26	0.03	2603
2025-10-16	GMAB	32.74	0.25	0.00	2733
2025-10-17	GMAB	33.17	0.23	0.26	2961
2025-10-20	GMAB	30.54	0.22	0.04	2422
2025-10-21	GMAB	30.14	0.22	0.14	2468
2025-10-22	GMAB	29.91	0.22	0.00	2499
2025-10-23	GMAB	29.91	0.20	0.00	2771
2025-10-24	GMAB	29.89	0.19	0.03	2795
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-29	GMAB	29.33	58.3	235.2	1.68
2025-09-30	GMAB	30.66	58.3	300.5	1.68
2025-10-01	GMAB	31.77	56.8	268.1	1.67
2025-10-02	GMAB	32.04	56.8	156.8	1.67
2025-10-03	GMAB	33.57	56.8	232.3	1.67
2025-10-06	GMAB	33.34	56.8	219.2	1.67
2025-10-07	GMAB	32.63	56.8	88.2	1.67
2025-10-08	GMAB	32.75	56.8	116.0	1.67
2025-10-09	GMAB	31.84	56.8	62.5	1.67
2025-10-10	GMAB	31.82	56.8	175.0	1.67
2025-10-13	GMAB	32.69	56.8	247.5	1.67
2025-10-14	GMAB	32.76	56.8	252.0	1.67
2025-10-15	GMAB	32.74	56.4	214.2	1.67
2025-10-16	GMAB	32.75	56.4	144.0	1.67
2025-10-17	GMAB	33.18	56.4	117.2	1.67
2025-10-20	GMAB	30.54	56.4	6.2	1.67
2025-10-21	GMAB	30.13	56.4	74.9	1.67
2025-10-22	GMAB	29.92	59.2	126.1	1.69
2025-10-23	GMAB	29.88	59.2	123.2	1.69
2025-10-24	GMAB	29.88	59.2	107.3	1.69
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-29	GMAB	0	-0.26	0
2025-09-30	GMAB	0	-0.26	0.57
2025-10-01	GMAB	0	-0.26	0.57
2025-10-02	GMAB	0	-0.26	0.57
2025-10-03	GMAB	0	-0.26	0.57
2025-10-06	GMAB	0	-0.19	0.57
2025-10-07	GMAB	0	-0.19	0.57
2025-10-08	GMAB	0	-0.19	0.57
2025-10-09	GMAB	0	-0.19	0.57
2025-10-10	GMAB	0	-0.19	0.90
2025-10-13	GMAB	0	0.37	0.90
2025-10-14	GMAB	0	0.37	0.90
2025-10-16	GMAB	0	0.37	0.90
2025-10-17	GMAB	0	0.37	0.90
2025-10-20	GMAB	0	0.37	0.90
2025-10-21	GMAB	0	0.37	0.90
2025-10-22	GMAB	0	0.37	0.90
2025-10-23	GMAB	0	0.37	0.90
2025-10-24	GMAB	0	0.37	0.90
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.54

Avg. EPS Est. Current Quarter

0.45

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

Institutional Transactions

0.37

Beta

0.97

Average Sales Estimate Current Quarter

6217

Average Sales Estimate Next Quarter

6612

Fair Value

34.79

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

39.1

Max Drawdown 5-Year %

-63.1

Target Price

33.84

P/E

14.92

Forward P/E

17.78

PEG

1.66

P/S

5.43

P/B

3.47

P/Free Cash Flow

18.3

EPS

Average EPS Est. Cur. Y

1.69

EPS Next Y. (Est.)

1.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.52

Relative Volume

2.15

Return on Equity vs Sector %

-1.1

Return on Equity vs Industry %

11.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

107.3

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2639

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Novo Nordisk A/S

NVO

$52.96

Name : Novo Nordisk A/S

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $236,407,062,528.00

EPSttm : 3.88

Novo Nordisk A/S

$52.96

0.51%

$0.27

Float Short %

0.93

Margin Of Safety %

Put/Call OI Ratio

0.78

EPS Next Q Diff

5.19

EPS Last/This Y

19.91

EPS This/Next Y

1.12

Price

52.98

Target Price

69.71

Analyst Recom

1.94

Performance Q

-23.25

Relative Volume

0.46

Beta

0.66

Ticker: NVO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-29	NVO	55.5	0.81	0.53	1166471
2025-09-30	NVO	55.41	0.80	0.63	1226165
2025-10-01	NVO	59.11	0.79	0.26	1257392
2025-10-02	NVO	58.74	0.78	0.46	1300567
2025-10-03	NVO	59.6	0.78	0.35	1337653
2025-10-06	NVO	59.71	0.76	0.31	1292418
2025-10-07	NVO	59.11	0.76	0.61	1309594
2025-10-08	NVO	59.61	0.78	0.51	1329053
2025-10-09	NVO	58.7	0.77	0.59	1340031
2025-10-10	NVO	56.98	0.78	0.80	1353943
2025-10-13	NVO	57.5	0.79	0.80	1319815
2025-10-14	NVO	56.54	0.79	0.79	1337935
2025-10-15	NVO	56.73	0.79	0.82	1352866
2025-10-16	NVO	56.09	0.81	0.71	1368031
2025-10-17	NVO	54.35	0.80	0.74	1360269
2025-10-20	NVO	55.74	0.77	0.67	1195188
2025-10-21	NVO	54.8	0.77	0.53	1248404
2025-10-22	NVO	53.37	0.77	0.82	1274147
2025-10-23	NVO	53.23	0.77	0.70	1310141
2025-10-24	NVO	52.95	0.78	0.51	1326320
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-29	NVO	55.51	-12.8	268.9	24.28
2025-09-30	NVO	55.49	-12.8	68.2	24.28
2025-10-01	NVO	59.17	-19.6	2004.6	23.93
2025-10-02	NVO	58.77	-19.6	-	23.93
2025-10-03	NVO	59.64	-19.5	-	23.94
2025-10-06	NVO	59.67	-28.3	-269.7	23.94
2025-10-07	NVO	59.04	-28.3	-968.8	23.74
2025-10-08	NVO	59.62	-28.3	-134.0	23.74
2025-10-09	NVO	58.68	-28.3	-980.0	23.74
2025-10-10	NVO	56.93	-28.3	-1355.3	23.74
2025-10-13	NVO	57.50	-28.3	-995.3	23.74
2025-10-14	NVO	56.67	-30.1	-1305.6	23.74
2025-10-15	NVO	56.73	-30.1	-328.7	23.74
2025-10-16	NVO	56.07	-29.7	-778.9	23.56
2025-10-17	NVO	54.36	-29.7	-1556.2	23.56
2025-10-20	NVO	55.74	-29.7	420.4	23.56
2025-10-21	NVO	54.78	-29.7	-1034.4	23.56
2025-10-22	NVO	53.38	-29.7	-1294.2	23.48
2025-10-23	NVO	53.22	-29.7	-655.3	23.48
2025-10-24	NVO	52.98	-29.7	-724.5	23.48
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-29	NVO	0	-6.22	0.85
2025-09-30	NVO	0	-6.22	0.85
2025-10-01	NVO	0	-6.22	0.85
2025-10-02	NVO	0	-6.22	0.85
2025-10-03	NVO	0	-6.22	0.85
2025-10-06	NVO	0	-1.45	0.85
2025-10-07	NVO	0	-1.45	0.85
2025-10-08	NVO	0	-1.45	0.85
2025-10-09	NVO	0	-1.45	0.85
2025-10-10	NVO	0	-1.45	0.93
2025-10-13	NVO	0	-1.41	0.93
2025-10-14	NVO	0	-1.41	0.93
2025-10-16	NVO	0	-1.41	0.93
2025-10-17	NVO	0	-1.41	0.93
2025-10-20	NVO	0	-1.46	0.93
2025-10-21	NVO	0	-1.46	0.93
2025-10-22	NVO	0	-1.46	0.93
2025-10-23	NVO	0	-1.46	0.93
2025-10-24	NVO	0	-1.46	0.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.97

Avg. EPS Est. Current Quarter

4.92

Avg. EPS Est. Next Quarter

6.16

Insider Transactions

Institutional Transactions

-1.46

Beta

0.66

Average Sales Estimate Current Quarter

76582

Average Sales Estimate Next Quarter

80494

Fair Value

62.5

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

64.2

Max Drawdown 5-Year %

-68.5

Target Price

69.71

P/E

14.59

Forward P/E

13.19

PEG

1.34

P/S

3.92

P/B

8.89

P/Free Cash Flow

18.79

EPS

3.63

Average EPS Est. Cur. Y

23.48

EPS Next Y. (Est.)

24.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.6

Relative Volume

0.46

Return on Equity vs Sector %

41.8

Return on Equity vs Industry %

31.5

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.68

EBIT Estimation

-724.5

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78387

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

$202.00

Name : Ascendis Pharma A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $12,231,990,272.00

EPSttm : -5.27

Ascendis Pharma A/S

$202.00

0.49%

$0.99

Float Short %

4.26

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

0.98

EPS Last/This Y

5.27

EPS This/Next Y

5.58

Price

201.76

Target Price

249.71

Analyst Recom

Performance Q

23.05

Relative Volume

0.78

Beta

0.43

Ticker: ASND

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-29	ASND	191.57	0.39	0.16	9550
2025-09-30	ASND	198.84	0.40	0.02	9556
2025-10-01	ASND	204.23	0.39	0.02	9596
2025-10-02	ASND	201.2	0.39	0.46	9627
2025-10-03	ASND	204.15	0.41	0.09	9996
2025-10-06	ASND	211.01	0.41	0.12	10009
2025-10-07	ASND	209.75	0.41	0.00	10024
2025-10-08	ASND	209.64	0.42	0.14	10146
2025-10-09	ASND	214.53	0.42	0.11	10146
2025-10-10	ASND	209.44	0.42	0.18	10165
2025-10-13	ASND	208.67	0.42	30.17	10168
2025-10-14	ASND	208.56	0.52	0.47	10898
2025-10-15	ASND	206.12	0.52	0.06	10911
2025-10-16	ASND	207.04	0.52	30.15	10935
2025-10-17	ASND	210.14	0.45	0.08	10434
2025-10-20	ASND	205.21	0.43	1.18	5750
2025-10-21	ASND	200.39	0.47	0.96	6277
2025-10-22	ASND	202.98	0.47	0.21	6278
2025-10-23	ASND	201.27	0.47	0.56	6324
2025-10-24	ASND	201.87	0.47	0.11	6337
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-29	ASND	191.54	83.5	423.8	-2.51
2025-09-30	ASND	198.90	83.5	432.2	-2.51
2025-10-01	ASND	204.18	83.5	430.0	-2.51
2025-10-02	ASND	201.04	83.5	421.3	-2.51
2025-10-03	ASND	204.01	83.5	427.6	-2.51
2025-10-06	ASND	211.20	83.5	435.1	-2.51
2025-10-07	ASND	209.66	80.5	423.5	-2.66
2025-10-08	ASND	210.11	80.5	424.9	-2.66
2025-10-09	ASND	214.61	80.5	2582.6	-2.66
2025-10-10	ASND	209.20	82.2	419.1	-2.62
2025-10-13	ASND	208.67	82.2	423.6	-2.62
2025-10-14	ASND	208.73	83.6	424.6	-2.59
2025-10-15	ASND	206.99	83.6	422.5	-2.59
2025-10-16	ASND	207.14	84.8	424.1	-2.56
2025-10-17	ASND	210.19	84.8	427.1	-2.56
2025-10-20	ASND	205.21	85.0	418.5	-2.51
2025-10-21	ASND	200.32	85.0	418.7	-2.51
2025-10-22	ASND	202.70	86.9	425.6	-2.39
2025-10-23	ASND	201.07	86.9	421.8	-2.39
2025-10-24	ASND	201.76	86.9	424.1	-2.39
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-29	ASND	0.00	-5.05	3.81
2025-09-30	ASND	0.00	-5.05	3.81
2025-10-01	ASND	0.00	-5.05	3.81
2025-10-02	ASND	0.00	-5.05	3.81
2025-10-03	ASND	0.00	-5.05	3.81
2025-10-06	ASND	0.00	-3.59	3.81
2025-10-07	ASND	0.00	-3.59	3.81
2025-10-08	ASND	0.00	-3.59	3.81
2025-10-09	ASND	0.00	-3.59	3.81
2025-10-10	ASND	0.00	-3.59	4.26
2025-10-13	ASND	0.00	-3.45	4.26
2025-10-14	ASND	0.00	-3.45	4.26
2025-10-15	ASND	0.00	-3.45	4.26
2025-10-16	ASND	0.00	-3.45	4.26
2025-10-17	ASND	0.00	-3.45	4.26
2025-10-20	ASND	0.00	-3.53	4.26
2025-10-21	ASND	0.00	-3.53	4.26
2025-10-22	ASND	0.00	-3.53	4.26
2025-10-23	ASND	0.00	-3.53	4.26
2025-10-24	ASND	0.00	-3.53	4.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.93

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

Institutional Transactions

-3.53

Beta

0.43

Average Sales Estimate Current Quarter

209

Average Sales Estimate Next Quarter

263

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

6.8

Max Drawdown 5-Year %

-61.7

Target Price

249.71

P/E

Forward P/E

44.02

PEG

P/S

22.88

P/B

P/Free Cash Flow

EPS

-4.97

Average EPS Est. Cur. Y

-2.39

EPS Next Y. (Est.)

3.19

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-54.94

Relative Volume

0.78

Return on Equity vs Sector %

120.2

Return on Equity vs Industry %

133

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.12

EBIT Estimation

424.1

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y